RhumbLine Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-115,142
| Closed | -$2.17M | – | 2975 |
|
|
2019
Q3 | $2.17M | Buy |
115,142
+6,988
| +6% | +$79.9K | ﹤0.01% | 1698 |
|
|
2019
Q2 | $1.27M | Buy |
108,154
+357
| +0.3% | +$4.32K | ﹤0.01% | 1960 |
|
|
2019
Q1 | $1.47M | Buy |
107,797
+10,035
| +10% | +$130K | ﹤0.01% | 1864 |
|
|
2018
Q4 | $1M | Buy |
97,762
+42,624
| +77% | +$546K | ﹤0.01% | 2012 |
|
|
2018
Q3 | $918K | Sell |
55,138
-10,450
| -16% | -$189K | ﹤0.01% | 2037 |
|
|
2018
Q2 | $1.04M | Buy |
65,588
+2,602
| +4% | +$39.5K | ﹤0.01% | 1993 |
|
|
2018
Q1 | $800K | Buy |
62,986
+1,540
| +3% | +$22.3K | ﹤0.01% | 2035 |
|
|
2017
Q4 | $704K | Sell |
61,446
-9,888
| -14% | -$110K | ﹤0.01% | 2098 |
|
|
2017
Q3 | $874K | Buy |
71,334
+9,918
| +16% | +$103K | ﹤0.01% | 2042 |
|
|
2017
Q2 | $703K | Buy |
61,416
+4,825
| +9% | +$89.2K | ﹤0.01% | 2142 |
|
|
2017
Q1 | $1.18M | Buy |
56,591
+2,337
| +4% | +$51.7K | ﹤0.01% | 1844 |
|
|
2016
Q4 | $1.13M | Buy |
54,254
+2,605
| +5% | +$67.7K | ﹤0.01% | 1791 |
|
|
2016
Q3 | $1.69M | Buy |
51,649
+7,624
| +17% | +$232K | ﹤0.01% | 1519 |
|
|
2016
Q2 | $1.1M | Buy |
44,025
+19,950
| +83% | +$540K | ﹤0.01% | 1729 |
|
|
2016
Q1 | $590K | Buy |
24,075
+550
| +2% | +$12.7K | ﹤0.01% | 2108 |
|
|
2015
Q4 | $777K | Buy |
23,525
+2,985
| +15% | +$101K | ﹤0.01% | 1966 |
|
|
2015
Q3 | $673K | Buy |
20,540
+2,885
| +16% | +$123K | ﹤0.01% | 2038 |
|
|
2015
Q2 | $935K | Buy |
17,655
+8,430
| +91% | +$307K | ﹤0.01% | 1906 |
|
|
2015
Q1 | $266K | Buy |
9,225
+2,175
| +31% | +$59.7K | ﹤0.01% | 2678 |
|
|
2014
Q4 | $205K | Buy |
+7,050
| New | +$127K | ﹤0.01% | 2805 |
|
RhumbLine Advisers's ALDR Position: Q4 2019 in Review
RhumbLine Advisers sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 115,142 shares — an estimated $2.17M sold.
RhumbLine Advisers first reported a position in ALDR in Q4 2014 and held it in 20 quarters. The position peaked at $2.17M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- RhumbLine Advisers reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- RhumbLine Advisers sold 115,142 Alder Biopharmaceuticals shares in Q4 2019, an estimated $2.17M.
- RhumbLine Advisers first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 20 quarters.
- RhumbLine Advisers's Alder Biopharmaceuticals position peaked at $2.17M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.